Main Industry
Manufacturing
Main Product/Service
Sleep apnea Oral Appliance Therapy
Adaptive Adjustable Structure, Flexibly Accommodating Various Treatment Needs.
Patented shark fin fixing base with replaceable displacement components for high-precision adjustments.
Using 3D digital scanning technology and occlusion analysis systems, we ensure that the airway is maximized for optimal airflow and effectiveness.
Utilizes next-generation Medura nano-medical technology material, combining innovation and durability.
Perfectly integrates toughness, comfort, and lightness for an exceptional user experience.
Product Advantages
Innovative design brings you a new experience of comfort and health
Lightweight
Portable
Easy to Wear
Easy to Clean
Wear-Resistant
High Toughness
Deformation-Resistant
Integrated Molding
Metal-Free
Custom Fit
Adaptive Adjustable Structure, Flexibly Accommodating Various Treatment Needs.
Patented shark fin fixing base with replaceable displacement components for high-precision adjustments.
Using 3D digital scanning technology and occlusion analysis systems, we ensure that the airway is maximized for optimal airflow and effectiveness.
Utilizes next-generation Medura nano-medical technology material, combining innovation and durability.
Perfectly integrates toughness, comfort, and lightness for an exceptional user experience.
Product Advantages
Innovative design brings you a new experience of comfort and health
Lightweight
Portable
Easy to Wear
Easy to Clean
Wear-Resistant
High Toughness
Deformation-Resistant
Integrated Molding
Metal-Free
Custom Fit
Founded Year
2019
Unified Business No.
50919498
Status
Active
Number of Employees
36
Total Paid-in
Capital
11,000,000 (NT$)
Location of Company
Taiwan
, Taoyuan City
Year of establishment, company status, responsible person, paid-in capital amount, and registered address are sourced from the "Commerce Industrial Services Portal, Department of Commerce, MOE. Exit status refers to various situations, including emerging stock exchanges (e.g., potential exits), mergers and acquisitions (M&A), and IPOs. The overseas development countries are collected through information provided by startups themselves and the information filled in when registering for matchmaking events. Therefore, the information cannot be updated in real time. If you wish to make corrections, please email findit.tier@gmail.com. Thank you.
Exclusive content for members
Members-only content. Please log in to access.
About the Company
Traditional treatments for Obstructive Sleep Apnea (OSA) primarily rely on surgical procedures and Continuous Positive Airway Pressure (CPAP) therapy. However, during the COVID-19 pandemic in 2020, widespread lockdowns led many patients to avoid non-essential medical visits, particularly those involving high-risk areas such as the oral cavity and upper respiratory tract. In response, Professor Han-Bin Kuo, then Director of the Department of Pulmonary Medicine at Taipei Medical University Hospital, and Professor Da-Yuan Wang, a Columbia University-trained specialist and then Dean of the College of Oral Medicine, identified this clinical need and emerging trend, initiating a cross-disciplinary collaboration to develop an innovative, non-invasive alternative to surgery and CPAP.
Following three years of clinical research, the project gained strong endorsement from Professor Fei-Peng Lee, Vice President of Taipei Medical University and former Director of the Department of Otolaryngology at Shuang Ho Hospital. Serving as both research advisor and board member, he facilitated deeper collaboration across pulmonology, otolaryngology, and dentistry. This partnership ultimately led to the development of the OSAWELL Mandibular Advancement Device—a solution integrating clinical data, digitally optimized design, and a structured database. In 2023, the device received dual patents in Taiwan and the United States. In January 2024, the technology was officially licensed to ShareSmile Biotech Co., Ltd. , which has since focused on refining the product's manufacturing, materials, and clinical implementation, with a strategic push toward global market expansion to benefit OSA patients worldwide.
At the core of OSAWELL's technology is a customized digital analysis system combined with 3D occlusal scanning. It accurately calculates the mandibular advancement required for each patient based on their anatomical and airway structure, maximizing airway patency. Digital simulation minimizes temporomandibular joint (TMJ) discomfort and muscle fatigue caused by excessive movement, thereby enhancing user comfort and long-term adherence. Clinical studies demonstrate that OSAWELL effectively reduces the Apnea-Hypopnea Index (AHI) and improves blood oxygen saturation. Its digital design also enhances treatment accuracy and patient acceptance, making it a mainstream option for mild to moderate OSA and a potential alternative for severe cases.
In 2022, the OSAWELL team was invited to present at the World Sleep Congress in Rio de Janeiro, Brazil, where the product received critical acclaim from global experts. Notably, Dr. Stanley Liu, Associate Professor of both Dentistry and Otolaryngology at Stanford University, and Dr. Leopoldo Correa, Associate Professor at Tufts University, provided valuable insights and professional feedback on OSAWELL’s development. After continuous refinement, the upgraded OSAWELL Pro was officially launched in 2024. Made from Medura, a patented nano-laser polymerized material, it offers enhanced clinical adaptability and durability. The device has since received collaboration requests and recognition from numerous teaching hospitals and international research institutions.
The development of OSAWELL exemplifies the integration of digital technology and sleep medicine, marking a new era of precision and non-invasive OSA treatment. As global awareness of OSA continues to rise, the OSAWELL team is dedicated to further innovations, including AI analytics, smart materials, and remote monitoring integration, with a mission to provide safer, more comfortable, and effective treatment options to patients worldwide.
Following three years of clinical research, the project gained strong endorsement from Professor Fei-Peng Lee, Vice President of Taipei Medical University and former Director of the Department of Otolaryngology at Shuang Ho Hospital. Serving as both research advisor and board member, he facilitated deeper collaboration across pulmonology, otolaryngology, and dentistry. This partnership ultimately led to the development of the OSAWELL Mandibular Advancement Device—a solution integrating clinical data, digitally optimized design, and a structured database. In 2023, the device received dual patents in Taiwan and the United States. In January 2024, the technology was officially licensed to ShareSmile Biotech Co., Ltd. , which has since focused on refining the product's manufacturing, materials, and clinical implementation, with a strategic push toward global market expansion to benefit OSA patients worldwide.
At the core of OSAWELL's technology is a customized digital analysis system combined with 3D occlusal scanning. It accurately calculates the mandibular advancement required for each patient based on their anatomical and airway structure, maximizing airway patency. Digital simulation minimizes temporomandibular joint (TMJ) discomfort and muscle fatigue caused by excessive movement, thereby enhancing user comfort and long-term adherence. Clinical studies demonstrate that OSAWELL effectively reduces the Apnea-Hypopnea Index (AHI) and improves blood oxygen saturation. Its digital design also enhances treatment accuracy and patient acceptance, making it a mainstream option for mild to moderate OSA and a potential alternative for severe cases.
In 2022, the OSAWELL team was invited to present at the World Sleep Congress in Rio de Janeiro, Brazil, where the product received critical acclaim from global experts. Notably, Dr. Stanley Liu, Associate Professor of both Dentistry and Otolaryngology at Stanford University, and Dr. Leopoldo Correa, Associate Professor at Tufts University, provided valuable insights and professional feedback on OSAWELL’s development. After continuous refinement, the upgraded OSAWELL Pro was officially launched in 2024. Made from Medura, a patented nano-laser polymerized material, it offers enhanced clinical adaptability and durability. The device has since received collaboration requests and recognition from numerous teaching hospitals and international research institutions.
The development of OSAWELL exemplifies the integration of digital technology and sleep medicine, marking a new era of precision and non-invasive OSA treatment. As global awareness of OSA continues to rise, the OSAWELL team is dedicated to further innovations, including AI analytics, smart materials, and remote monitoring integration, with a mission to provide safer, more comfortable, and effective treatment options to patients worldwide.
